Stock EPMT PT ENSEVAL PUTERA MEGATRADING TBK.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Enseval Putera Megatrading Tbk.

Equities

EPMT

ID1000096506

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
2,320 IDR 0.00% Intraday chart for PT Enseval Putera Megatrading Tbk. -0.43% -10.42%
03-28 PT Enseval Putera Megatrading Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 PT Enseval Putera Megatrading Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,688,144 5,552,712 5,715,230 7,313,328 7,448,760 7,015,378
Enterprise Value (EV) 1 4,261,178 4,375,026 3,949,573 5,758,312 6,579,735 6,469,271
P/E ratio 8.71 x 9.56 x 8.4 x 8.63 x 8.79 x 10.2 x
Yield 4.29% 4.39% 9.48% 7.59% 7.45% -
Capitalization / Revenue 0.28 x 0.25 x 0.25 x 0.28 x 0.27 x 0.25 x
EV / Revenue 0.21 x 0.2 x 0.18 x 0.22 x 0.23 x 0.23 x
EV / EBITDA 4.43 x 5 x 4.36 x 4.86 x 5.26 x 6.16 x
EV / FCF 10.9 x -38.9 x 5.86 x 38.3 x -30.3 x 40.4 x
FCF Yield 9.2% -2.57% 17.1% 2.61% -3.3% 2.47%
Price to Book 0.98 x 0.91 x 0.87 x 1.07 x 1.05 x 0.97 x
Nbr of stocks (in thousands) 2,708,640 2,708,640 2,708,640 2,708,640 2,708,640 2,708,640
Reference price 2 2,100 2,050 2,110 2,700 2,750 2,590
Announcement Date 29/03/19 03/04/20 29/03/21 31/03/22 28/03/23 28/03/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 20,604,487 22,226,912 22,545,419 25,673,757 28,027,488 28,507,873
EBITDA 1 962,103 875,467 904,943 1,185,835 1,251,054 1,050,294
EBIT 1 834,841 747,361 767,386 1,034,226 1,094,573 894,749
Operating Margin 4.05% 3.36% 3.4% 4.03% 3.91% 3.14%
Earnings before Tax (EBT) 1 879,481 813,103 882,740 1,091,263 1,101,140 892,425
Net income 1 653,064 580,630 680,598 847,881 847,533 688,499
Net margin 3.17% 2.61% 3.02% 3.3% 3.02% 2.42%
EPS 2 241.1 214.4 251.3 313.0 312.9 254.2
Free Cash Flow 1 392,045 -112,331 673,874 150,176 -217,420 159,991
FCF margin 1.9% -0.51% 2.99% 0.58% -0.78% 0.56%
FCF Conversion (EBITDA) 40.75% - 74.47% 12.66% - 15.23%
FCF Conversion (Net income) 60.03% - 99.01% 17.71% - 23.24%
Dividend per Share 2 90.00 90.00 200.0 205.0 205.0 -
Announcement Date 29/03/19 03/04/20 29/03/21 31/03/22 28/03/23 28/03/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,426,966 1,177,686 1,765,657 1,555,016 869,025 546,107
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 392,045 -112,331 673,874 150,176 -217,420 159,991
ROE (net income / shareholders' equity) 12% 9.75% 10.7% 12.6% 12.1% 9.54%
ROA (Net income/ Total Assets) 6.63% 5.49% 5.35% 6.83% 6.8% 5.24%
Assets 1 9,855,787 10,583,462 12,712,427 12,423,167 12,470,870 13,148,068
Book Value Per Share 2 2,136 2,262 2,415 2,522 2,626 2,676
Cash Flow per Share 2 466.0 384.0 598.0 489.0 365.0 253.0
Capex 1 121,349 307,742 201,029 107,175 111,985 169,561
Capex / Sales 0.59% 1.38% 0.89% 0.42% 0.4% 0.59%
Announcement Date 29/03/19 03/04/20 29/03/21 31/03/22 28/03/23 28/03/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT ENSEVAL PUTERA MEGATRADING TBK. Stock PT Enseval Putera Megatrading Tbk.
-10.42% 387M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. EPMT Stock
  4. Financials PT Enseval Putera Megatrading Tbk.